These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12195692)

  • 1. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
    Weitz IC; Israel VK; Waisman JR; Presant CA; Rochanda L; Liebman HA
    Thromb Haemost; 2002 Aug; 88(2):213-20. PubMed ID: 12195692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
    Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
    Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial.
    Falanga A; Levine MN; Consonni R; Gritti G; Delaini F; Oldani E; Julian JA; Barbui T
    Thromb Haemost; 1998 Jan; 79(1):23-7. PubMed ID: 9459316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group.
    Thromb Haemost; 1993 Dec; 70(6):909-14. PubMed ID: 8165610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.
    Wada H; Ikuma H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Onoda K; Yamada N; Ohta T; Nishioka J; Sakuragawa N; Shiku H
    Semin Thromb Hemost; 2000; 26(1):113-8. PubMed ID: 10805292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
    Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
    Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
    Kakkar AK; Levine MN; Kadziola Z; Lemoine NR; Low V; Patel HK; Rustin G; Thomas M; Quigley M; Williamson RC
    J Clin Oncol; 2004 May; 22(10):1944-8. PubMed ID: 15143088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation.
    Kaneko J; Sugawara Y; Tamura S; Togashi J; Matsui Y; Akamatsu N; Kishi Y; Makuuchi M
    Clin Transplant; 2005 Dec; 19(6):804-9. PubMed ID: 16313329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
    Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
    Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
    Bombeli T; Raddatz-Mueller P; Fehr J
    Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.
    Mukherjee SD; Swystun LL; Mackman N; Wang JG; Pond G; Levine MN; Liaw PC
    Pathophysiol Haemost Thromb; 2010; 37(2-4):88-97. PubMed ID: 21430357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.
    Harada N; Okajima K; Uchiba M
    Crit Care Med; 2006 Jul; 34(7):1883-91. PubMed ID: 16641616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ; Velan T; Aldea GS; Chandler WL
    Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
    Peternel P; Terbizan M; Tratar G; Bozic M; Horvat D; Salobir B; Stegnar M
    Thromb Res; 2002 Feb; 105(3):241-6. PubMed ID: 11927130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
    de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-dimers, thrombin-antithrombin complexes, and risk factors for thromboembolism in hospitalized patient.
    Pottier P; Fouassier M; Hardouin JB; Volteau C; Planchon B
    Clin Appl Thromb Hemost; 2009 Dec; 15(6):666-75. PubMed ID: 18796458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
    Ernofsson M; Strekerud F; Toss H; Abildgaard U; Wallentin L; Siegbahn A
    Thromb Haemost; 1998 Mar; 79(3):491-4. PubMed ID: 9531028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.
    Bombeli T; Raddatz Mueller P; Fehr J
    Haemostasis; 2001; 31(2):90-8. PubMed ID: 11684864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.